CytomX Therapeutics price target lowered to $3.25 from $3.50 at Piper Sandler
The Fly

CytomX Therapeutics price target lowered to $3.25 from $3.50 at Piper Sandler

Piper Sandler lowered the firm’s price target on CytomX Therapeutics (CTMX) to $3.25 from $3.50 and keeps an Overweight rating on the shares following Q3 results. Cash of $118M provides runway to end of 2025, so a bit tight, but excludes any future potential milestones, Piper told investors in a research note.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App